Global $13.8 Billion Antimicrobial Resistance Market, 2027 | Opportunity Breakdown by Disease, Pathogen, Drug Class, End-user and Region -

DUBLIN--()--The "Global Antimicrobial Resistance Market Size, Trends & Growth Opportunity by Disease, Pathogen, Drug Class and Region, Forecast till 2027" report has been added to's offering.

The global antimicrobial resistance market was valued at US$ 9.39 billion in 2020, and is estimated to reach US$ 13.8 billion in 2027, with a CAGR of 4.68% from 2021-2027.

Market Driver: Impact of the Antimicrobial Resistance (AMR) Market on the Healthcare Industry

The emergence and spread of drug-resistant pathogens which have acquired new resistance mechanisms, leading to antimicrobial resistance, continues to threaten our ability to treat common infections. Especially alarming is the rapid global spread of multi- and pan-resistant bacteria (also known as "superbugs") that cause infections that are not treatable with existing antimicrobial medicines such as antibiotics.

Antibiotics are becoming increasingly ineffective as drug-resistance spreads globally leading to more difficult to treat infections and death. New antibacterial are urgently needed - for instance, to treat carbapenem-resistant gram-negative bacterial infections as identified in the WHO priority pathogen list. High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market. These factors have impacted the growth of healthcare industry.

Market Challenge: High Medical Costs

The cost of health care for patients suffering from resistant infections is higher than care for patients suffering from non-resistant infections due to the extended duration of illness, and increased usage of expensive drugs.

Market Opportunity: Government Funding for Controlling the Antimicrobial Resistance Species

The government and various concerned authorities related to the AMR market support the funding related to control the AMR species. The various funding related to Businesses, Universities, and Healthcare Partners are as below:

  • Broad Agency Announcement (BAA): Contracts with educational institutions, nonprofit organizations, state and local government, and private industry for research and development to identify and evaluate strategies to combat antibiotic resistance.
  • Global Healthcare Detection and Response: An international, five-year funding opportunity for partners with experience in healthcare infection detection and response, and/or antibiotic and antifungal resistance across the One Health spectrum.
  • Modeling Infectious Diseases in Healthcare Network (MInD - Healthcare): Established a virtual laboratory where researchers can investigate factors that drive spread of healthcare-associated infections and simulate multiple prevention strategies to estimate their benefits in a timely and cost-effective manner.

Impact of COVID-19

The COVID-19 crisis has deepened the global understanding of the health and economic implications of an uncontrolled pandemic. It also accentuated the gaps in sustainable funding to address these risks, including investments in R&D of antimicrobial medicines and vaccines, whilst revealing what rapid progress can be made when there is enough political will and enterprise.

Opportunities emerging from the COVID-19 pandemic must be seized to bring to the forefront the needs for sustainable investments in R&D of new and effective antibiotics, according to the director of AMR Global Coordination at WHO. According to WHO, antibiotics present the Achilles heel for universal health coverage and global health security. It needs a global sustained effort including mechanisms for pooled funding and new and additional investments to meet the magnitude of the AMR threat.

Thus, the emergence of COVID-19 has given an opportunity for the antibiotics resistance market towards growth.

Disease Breakdown

Based on disease type, the market has been categorized into cUTI, cIAI, BSI, CDI, ABSSSI, HABP/VABP, and CABP. cUTI represented the largest segment in the market in 2020 owing to high overall treatment cost and limited treatment alternatives for Gram-negative pathogens, which account for majority of infection cases. Lack of low-cost treatment options for Gram-negative infections limits access to recently approved branded therapies such as Allergan's Avycaz, Merck's Zerbaxa, and Melinta Therapeutics' Vabomere.

Pathogens Breakdown

Infections due to K. pneumoniae pathogens that are carbapenem-resistant and ESBL-producing held the largest share in 2020. These infections pose treatment challenges for physicians due to high resistance to current treatment substitutes. These infections even though fewer in terms of number of cases in comparison to Gram positive pathogens, they impose a high cost burden as physicians are increasingly shifting towards novel antibiotics such as Allergan's Avycaz and Melinta Therapeutics' Vabomere. CDI, conversely, it is anticipated to register the highest CAGR during the forecast period.

Drug Class Breakdown

Based on drug class, the market has been segmented into oxazolidinones, lipoglycopeptides, tetracyclines, cephalosporins, combination therapies, and others, which includes miscellaneous drug classes. Cephalosporins are leading the market by 21.38% of the overall market revenue in 2020.

End User Breakdown

By End-User the market is segmented into Hospitals, Clinics, Research Organizations, and other. Hospitals & Clinics form the largest growing segment as the majority of treatment and procedures are carried out in hospitals. Additionally, in 2016, the average consumption of antibiotics for systemic use in hospitals was 2.1 defined daily doses (DDD) per 1,000 people per day. Research Organizations encourage the research & development of new antimicrobial drugs and diagnostics, thus would drive the growth of the market. Global Antibiotic Research & Development Partnership address global public health needs by delivering and developing new or improved antibiotic treatments.

Regional Breakdown

North America was the largest region in terms of revenue in 2020. Numerous drug launches in the market and high treatment cost are supplementing the growth of the regional market.

The U.S. will be a key revenue contributor in the region during the forecast period as guidelines, such as those defined by IDSA for the treatment of CDI, are promoting the use of novel therapies.

Europe was the second largest regional market in the global arena in 2020, supported largely by growing number of antibiotic-resistant infections.

Among the OECD countries, Greece, Italy, and Portugal were ranked as the top 3 consumers of antibiotics in the world, contributing to increased antibiotic resistance in the region.

Companies Profiled

  • Allecra Therapeutics
  • Procarta Biosystems
  • Achaogen Inc.
  • Basilea Pharmaceutica Ltd.
  • Melinta Therapeutics Inc.
  • Seres Therapeutics
  • PARATEK Therapeutics
  • Entasis Therapeutics
  • Tetraphase Pharmaceuticals
  • Nabriva Therapeutics plc

Key Questions Addressed

  • What are the key opportunities in the market?
  • What will be the growth rate from 2020 to 2027?
  • Which segment/region will have highest growth?
  • What are the factors that will impact/drive the market?
  • What is the competitive landscape in the Industry?
  • What is the role of key players in the value chain?

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900